CANCER:

Uterine Corpus Leiomyosarcoma

Related cancers:

No biomarker No biomarker	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	No biomarker No biomarker	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	pazopanib Sensitive: A2 - Guideline	pazopanib Sensitive: A2 - Guideline
ER positive ER positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	ER positive ER positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	Aromatase inhibitor Sensitive: A2 - Guideline	Aromatase inhibitor Sensitive: A2 - Guideline
PGR positive PGR positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	PGR positive PGR positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	Aromatase inhibitor Sensitive: A2 - Guideline	Aromatase inhibitor Sensitive: A2 - Guideline
PGR positive PGR positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	PGR positive PGR positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	medroxyprogesterone Sensitive: A2 - Guideline	medroxyprogesterone Sensitive: A2 - Guideline
ER positive ER positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	ER positive ER positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	medroxyprogesterone Sensitive: A2 - Guideline	medroxyprogesterone Sensitive: A2 - Guideline
PGR positive PGR positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	PGR positive PGR positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	megestrol Sensitive: A2 - Guideline	megestrol Sensitive: A2 - Guideline
ER positive ER positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	ER positive ER positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	megestrol Sensitive: A2 - Guideline	megestrol Sensitive: A2 - Guideline
AKT1 E17K AKT1 E17K	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	AKT1 E17K AKT1 E17K	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	AZD5363 Sensitive: C3 – Early Trials	AZD5363 Sensitive: C3 – Early Trials
CD70 expression CD70 expression	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	CD70 expression CD70 expression	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	ARX305 Sensitive: C3 – Early Trials	ARX305 Sensitive: C3 – Early Trials
ER positive + PGR positive ER positive + PGR positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	ER positive + PGR positive ER positive + PGR positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	anastrozole Sensitive: C3 – Early Trials	anastrozole Sensitive: C3 – Early Trials
PGR positive PGR positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	PGR positive PGR positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	anastrozole Sensitive: C3 – Early Trials	anastrozole Sensitive: C3 – Early Trials
ER positive ER positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	ER positive ER positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	anastrozole Sensitive: C3 – Early Trials	anastrozole Sensitive: C3 – Early Trials
FN1-ALK fusion FN1-ALK fusion	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	FN1-ALK fusion FN1-ALK fusion	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	lorlatinib Sensitive: C4 – Case Studies	lorlatinib Sensitive: C4 – Case Studies
FN1-ALK fusion FN1-ALK fusion	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	FN1-ALK fusion FN1-ALK fusion	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	alectinib Sensitive: C4 – Case Studies	alectinib Sensitive: C4 – Case Studies
FN1-ALK fusion FN1-ALK fusion	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	FN1-ALK fusion FN1-ALK fusion	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	crizotinib Resistant: C4 – Case Studies	crizotinib Resistant: C4 – Case Studies
FN1-ALK fusion FN1-ALK fusion	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	FN1-ALK fusion FN1-ALK fusion	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	pazopanib Resistant: C4 – Case Studies	pazopanib Resistant: C4 – Case Studies
BRCA2 mutation BRCA2 mutation	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	BRCA2 mutation BRCA2 mutation	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	PARP inhibitor Sensitive: D – Preclinical	PARP inhibitor Sensitive: D – Preclinical